727P Phase Ib INEOV neoadjuvant trial of the anti-PDL1, durvalumab (D) +/- anti-CTLA4 tremelimumab (T) with platinum chemotherapy for patients (pts) with unresectable ovarian cancer (OC): A GINECO study

We have shown that neoadjuvant carboplatin and paclitaxel (NACP) increased tumor-infiltrating lymphocytes and PDL1 expression in OC pts. Combined PDL1/CTLA4 blockade is active in relapsed OC. INEOV is the 1st trial of neoadjuvant D +/- T with NACP in pts with unresectable OC. Main endpoints are feasibility and safety. 2° endpoints include macroscopically complete resection (CCO) and major pathological response rates after 3 cycles (C3).